Butyl carbitol, also known as 2-(2-butoxyethoxy)ethanol or diethylene glycol monobutyl ether, is a colorless, slightly viscous liquid with a faint odor. It is a solvent used in various industries. Synthesized via the reaction of ethylene oxide with butanol, butyl carbitol finds applications in numerous fields, including paints, coatings, inks, and cleaning products. It acts as a solvent, plasticizer, and humectant, contributing to the desired properties of these materials. Research on butyl carbitol primarily focuses on its environmental impact, toxicity, and safety considerations. Its biodegradability and potential for bioaccumulation are areas of ongoing study, as are its effects on human health. While butyl carbitol is generally considered safe for industrial use, proper handling and disposal procedures are essential to minimize any potential risks.'
butyl carbitol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8177 |
| CHEMBL ID | 1904721 |
| CHEBI ID | 195270 |
| SCHEMBL ID | 15619 |
| MeSH ID | M0045727 |
| Synonym |
|---|
| LS-13547 |
| dowanol db |
| nsc407762 |
| ethanol, 2-(2-butoxyethoxy)- |
| 2-(2-butoxyethoxy)ethanol |
| butoxyethoxyethanol |
| butoxydiethylene glycol |
| butoxydiglycol |
| nsc-407762 |
| diethylene glycol butyl ether |
| diethylene glycol monobutyl ether |
| butyl carbitol |
| diethylene glycol n-butyl ether |
| o-butyl diethylene glycol |
| 112-34-5 |
| bucb |
| butyl dioxitol |
| diethylene gylcol monobutyl ether |
| wln: q2o2o4 |
| butoxy diethylene glycol |
| butyl digol |
| butyl diglycol |
| ethanol,2'-oxybis-, monobutyl ether |
| diglycol monobutyl ether |
| hsdb 333 |
| ccris 5321 |
| epa pesticide chemical code 011502 |
| caswell no. 121b |
| einecs 203-961-6 |
| glycol ether db |
| jeffersol db |
| caswell no. 125h |
| brn 1739225 |
| ethanol, 2,2'-oxybis-, monobutyl ether |
| diethylene glycol mono-n-butyl ether |
| nsc 407762 |
| ai3-01954 |
| monobutyl diethylene glycol ether |
| ektasolve db |
| diethylene glycol butyl ether, >=99% |
| NCGC00164235-01 |
| diethylene glycol monobutyl ether, >=98.0% (gc) |
| B0699 |
| CHEBI:195270 |
| A802556 |
| NCGC00164235-02 |
| NCGC00164235-03 |
| AKOS009156535 |
| butyldiglycol |
| ec 203-961-6 |
| unii-9tb90iyc0e |
| 9tb90iyc0e , |
| NCGC00253937-01 |
| dtxcid001519 |
| tox21_300084 |
| cas-112-34-5 |
| tox21_202404 |
| NCGC00259953-01 |
| dtxsid8021519 , |
| FT-0624889 |
| 2-(2-butoxyethoxy)ethan-1-ol |
| diethylene glycol mono-n-butyl ether [hsdb] |
| butoxydiglycol [inci] |
| diethylene glycol monobutyl ether [mi] |
| SCHEMBL15619 |
| diethyleneglycol monobutyl ether |
| diethyleneglycol n-butyl ether |
| diethyleneglycol monobutylether |
| 2-(2-n-butoxyethoxy)ethanol |
| 2-(2-butoxyethoxy)-ethanol |
| CHEMBL1904721 |
| butyl di-icinol |
| ethanol 2-butoxyethoxy |
| diethylene glycol butyl ester |
| diethylene db |
| butadigol |
| butyl oxitol glycol ether |
| 3,6-dioxadecanol |
| 3,6-dioxa-1-decanol |
| n-butyl carbitol |
| J-002756 |
| J-519970 |
| mfcd00002881 |
| diethylene glycol butyl ether, saj special grade, >=99.0% |
| diethylene glycol monobutyl ether, for surfactant analysis, >=99.0% |
| EN300-206638 |
| diethylene glycol monobutyl ether, 98% |
| Q1018210 |
| diethylene glycol-monobutyl ether |
| F71187 |
| 2-(n-butoxyethoxy)ethanol |
| Excerpt | Reference | Relevance |
|---|---|---|
| " All rats survived the respective treatment intervals with no adverse treatment-related in-life effects, including no alterations in a functional observational battery." | ( Diethylene glycol monobutyl ether (DGBE): two- and thirteen-week oral toxicity studies in Fischer 344 rats. Baker, PC; Johnson, KA; Kan, HL; Marty, MS; Maurissen, JP; Spencer, PJ, 2005) | 0.33 |
| " Clinical chemistry parameters (HDL-cholesterol, BUN) and some markers of oxidative stress differ between the exposed groups and the control one, but without adverse health effect." | ( Fertility and developmental toxicity studies of diethylene glycol monobutyl ether (DGBE) in rats. Gromadzińska, J; Lutz, P; Sitarek, K; Stetkiewicz, J; Świercz, R; Wąsowicz, W, 2012) | 0.38 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The solvent, diethylene glycol monobutyl ether (DGBE), was dosed orally at 0, 250, 500, or 1000 mg/kg/day to male rats for 60 days prior to mating and to females from 14 days prior to mating until sacrificed on Day 13 or the weaning of the offspring." | ( Fertility and teratogenic studies of diethylene glycol monobutyl ether in rats and rabbits. Benedict, JH; Briggs, DW; Gibson, WB; Nolen, GA; Schardein, JL, 1985) | 0.27 |
| Class | Description |
|---|---|
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 75.1108 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 23.8805 | 0.0002 | 21.2231 | 8,912.5098 | AID588515; AID743035 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 6.1909 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 2.4529 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 51.9282 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 61.0684 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.9089 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 30.7625 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (13.04%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (86.96%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||